Despite the continuous deployment of new treatment strategies and agents over many
decades, most disseminated cancers remain fatal. Cancer cells, through their access to the …

Despite continuous deployment of new treatment strategies and agents over many decades,
most disseminated cancers remain fatal. Cancer cells, through their access to the vast …

Many effective drugs for metastatic and/or advanced-stage cancers have been developed
over the past decade, although the evolution of resistance remains the major barrier to …

Acquired drug resistance is a major limitation for the successful treatment of cancer.
Resistance can emerge due to a variety of reasons including host environmental factors as …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Drug resistance is a serious impediment to the treatment of cancer. However, the
mechanisms involved remain poorly understood. While it is widely held that the …

Despite the great progress in our understanding of the molecular basis of human cancer, the
heterogeneity of individual tumors and the evolutionary pressures imposed by therapy have …

Despite advances in cancer biology and therapeutics, drug resistance remains problematic.
Resistance is often multifactorial, heterogeneous, and prone to undersampling …

Mutational processes and nongenetic phenotypic state transitions represent distinct
paradigms for understanding acquired resistance to targeted therapies. While ample …

Targeted therapies, immunotherapies, and improved chemotherapies are being developed
to reduce the suffering and mortality that come from human cancer. Although these …